Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...
GlobalData on MSN23h
DMTs are major clinical research focus for Parkinson’s disease, analysis showsAnalysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
News Medical on MSN16h
New biomarker could help predict Parkinson’s disease progressionA team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...
Medpage Today on MSN20h
Galantamine and Alzheimer's; Fork Sign Landmark; Instagram in Neurology EducationGalantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback